XML 47 R21.htm IDEA: XBRL DOCUMENT
v3.23.2

Stockholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2023
Compensation Related Costs [Abstract] |
Stockholders' Equity | Changes in Stockholders’ Equity (Deficit) The following tables present certain information regarding our stockholders’ equity as of June 30, 2023 and 2022:
| Six Months Ended June 30, 2023
| Common Stock |  | Additional Paid in Capital |  | Retained Earnings |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interest |  | Total
January 1, 2023 | $ | 1 |  |  | $ | 1,370 |  |  | $ | 517 |  |  | $ | (580) |  |  | $ | (318) |  |  | $ | 171 |  |  | $ | 1,161 |
Settlement of liability awards | — |  |  | 25 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 25 |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (14) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (14) |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (28) |  |  | — |  |  | — |  |  | (28) |
Purchase of SciPlay’s Class A common stock | — |  |  | (8) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (8) |
Stock-based compensation | — |  |  | 15 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |
Net income | — |  |  | — |  |  | 22 |  |  | — |  |  | — |  |  | 5 |  |  | 27 |
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | 6 |  |  | — |  |  | 6 |
March 31, 2023 | $ | 1 |  |  | $ | 1,388 |  |  | $ | 539 |  |  | $ | (608) |  |  | $ | (312) |  |  | $ | 176 |  |  | $ | 1,184 |
Vesting of RSUs, net of tax withholdings and other | — |  |  | 1 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1 |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (5) |  |  | — |  |  | — |  |  | (5) |
Purchase of SciPlay’s Class A common stock | — |  |  | (15) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (15) |
Stock-based compensation | — |  |  | 13 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 13 |
Net (loss) income | — |  |  | — |  |  | (1) |  |  | — |  |  | — |  |  | 6 |  |  | 5 |
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | 47 |  |  | — |  |  | 47 |
June 30, 2023 | $ | 1 |  |  | $ | 1,387 |  |  | $ | 538 |  |  | $ | (613) |  |  | $ | (265) |  |  | $ | 182 |  |  | $ | 1,230 |
| Six Months Ended June 30, 2022
| Common Stock |  | Additional Paid in Capital |  | Retained Earnings (Accumulated Loss) |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interest |  | Total
January 1, 2022 | $ | 1 |  |  | $ | 1,337 |  |  | $ | (3,158) |  |  | $ | (175) |  |  | $ | (261) |  |  | $ | 150 |  |  | $ | (2,106) |
Settlement of liability awards | — |  |  | 43 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 43 |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (31) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (31) |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (51) |  |  | — |  |  | — |  |  | (51) |
Stock-based compensation | — |  |  | 17 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17 |
Net income | — |  |  | — |  |  | 26 |  |  | — |  |  | — |  |  | 2 |  |  | 28 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (37) |  |  | — |  |  | (37) |
March 31, 2022 | $ | 1 |  |  | $ | 1,366 |  |  | $ | (3,132) |  |  | $ | (226) |  |  | $ | (298) |  |  | $ | 152 |  |  | $ | (2,137) |
Vesting of RSUs, net of tax withholdings and other | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (152) |  |  | — |  |  | — |  |  | (152) |
Purchase of SciPlay’s Class A common stock | — |  |  | (6) |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (7) |
Stock-based compensation | — |  |  | 15 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |
Net income | — |  |  | — |  |  | 3,291 |  |  | — |  |  | — |  |  | 4 |  |  | 3,295 |
Other comprehensive loss(1) | — |  |  | — |  |  | — |  |  | — |  |  | (48) |  |  | — |  |  | (48) |
June 30, 2022 | $ | 1 |  |  | $ | 1,375 |  |  | $ | 159 |  |  | $ | (378) |  |  | $ | (346) |  |  | $ | 155 |  |  | $ | 966 |
(1) Includes reclassification of $23 million accumulated other comprehensive loss into income due to the sale of discontinued operations (see Note 2).
Stock-based Compensation The following reflects total stock-based compensation expense recognized under all programs:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Related to L&W stock options | $ | — |  |  | $ | 1 |  |  | $ | — |  |  | $ | 1 |
Related to L&W RSUs | 21 |  |  | 15 |  |  | 40 |  |  | 27 |
Related to SciPlay RSUs | 7 |  |  | 1 |  |  | 14 |  |  | 4 |
Total(1) | $ | 28 |  |  | $ | 17 |  |  | $ | 54 |  |  | $ | 32 |
(1) Includes $15 million and $26 million classified as liability awards for the three and six months ended June 30, 2023, respectively, and $6 million and $10 million for the three and six months ended June 30, 2022, respectively.
Restricted Stock Units A summary of the changes in RSUs outstanding under our equity-based compensation plans during the six months ended June 30, 2023 is presented below:
| Number of Restricted Stock Units |  | Weighted Average Grant Date Fair Value
Unvested RSUs as of December 31, 2022 | 1.7 |  |  | $ | 46.66 |
Granted | 1.1 |  |  | $ | 57.15 |
Vested | (0.9) |  |  | $ | 45.05 |
Cancelled | (0.1) |  |  | $ | 46.83 |
Unvested RSUs as of June 30, 2023 | 1.8 |  |  | $ | 53.56 |
The weighted-average grant date fair value of RSUs granted during the six months ended June 30, 2023 and 2022 was $57.15 and $58.30, respectively. The fair value of each RSU grant is based on the market value of our common stock at the time of grant. As of June 30, 2023, we had $69 million in total unrecognized stock-based compensation expense relating to unvested RSUs that will be amortized over a weighted-average period of approximately two years. The fair value at vesting date of RSUs vested during the six months ended June 30, 2023 and 2022 was $51 million and $62 million, respectively. Series A Junior Participating Preferred Stock and Rights Agreement The 2018 Amended and Restated Rights Agreement, as described in Note 17 of our 2022 10-K, expired on June 19, 2023. Immediately prior to its expiration, no shares of Series A Junior Participating Preferred Stock were outstanding and no preferred share purchase rights had been exercised. At the time of the expiration of the agreement, the preferred share purchase rights expired and are no longer outstanding. Share Repurchase Programs On March 1, 2022, our Board of Directors approved a share repurchase program under which we are authorized to repurchase, from time to time through February 25, 2025, up to an aggregate amount of $750 million of our outstanding common stock. During the six months ended June 30, 2023, we repurchased 0.6 million shares of common stock under the program at an aggregate cost of $33 million. On May 9, 2022, SciPlay’s Board of Directors approved a share repurchase program under which it is authorized to repurchase, from time to time through May 9, 2024, up to an aggregate amount of $60 million of its outstanding Class A common stock. On May 3, 2023, SciPlay’s Board of Directors approved another share repurchase program under which it is authorized to repurchase, from time to time through May 3, 2024, up to an aggregate amount of $60 million of its outstanding Class A common stock. During the six months ended June 30, 2023, SciPlay repurchased 1.4 million shares of Class A common stock under the programs at an aggregate cost of $23 million.

X
- References No definition available. + Details
Name: | us-gaap_CompensationRelatedCostsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//710/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482969/710-10-50-1 + Details
Name: | us-gaap_CompensationRelatedCostsGeneralTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration